SCHEMBL22005105

SCHEMBL22005105

Cc1ccc2c(c1)cc(-c1cncnc1)n2C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 5/20 0.46
NR1I2 O75469 1/20 0.36
EGFR P00533 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
TBXA2R P21731 1/20 0.36
PTGS2 P35354 1/20 0.36
OPRD1 P41143 1/20 0.36
PDE4D Q08499 1/20 0.36
USP2 O75604 1/20 0.36
HTT P42858 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22004122 0.84 ACLY (0.46) ACLYUSP2HTTNCOA1NCOA3
SCHEMBL22005030 0.82 ACLY (0.40) ACLYNR1I2EGFRADRA2AADORA3
SCHEMBL22004392 0.81 ACLY (0.47) ACLYCYP11B1CYP11B2KDM4EALDH1A1
SCHEMBL22004159 0.81 ACLY (0.48) ACLYNR1I2USP2HTTNCOA1
SCHEMBL21244768 0.80 NR1I2 (0.48) ACLYNR1I2EGFRADRA2AADORA3
SCHEMBL22005143 0.80 ACLY (0.48) ACLYNR1I2KDM4ENPC1ALDH1A1
SCHEMBL22004313 0.71 ACLY (0.47) ACLYUSP2HTTNCOA1NCOA3
SCHEMBL22003806 0.70 HTT (0.50) ACLYUSP2HTTNCOA1NCOA3
SCHEMBL24345322 0.69 HTR2A (0.42) NR1I2EGFRADRA2AADORA3TBXA2R
SCHEMBL22005033 0.69 KDM4E (0.41) ACLYEGFRHTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG ACLY 1/4885NR1I2 2837/4885EGFR 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.